| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.49 | 0.08 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.08 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | phenformin | GDSC1000 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.08 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.081 | 0.08 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.08 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.08 |